Sodium-glucose co-transporter 2 inhibitors – a review article

Antihyperglycemic interventions have centered on increasing insulin availability, improving insulin sensitivity or restoring β-cell activity to normalize plasma glucose levels in patients with type 2 diabetes mellitus. An alternative strategy is to enhance urinary glucose excretion by targeting rena...

Full description

Saved in:
Bibliographic Details
Published in:Journal of education, health and sport health and sport, 2019-08, Vol.9 (9)
Main Authors: Marcin Makuch, Marcelina Makuch, Ewa Krzewicka-Romaniuk, Grzegorz Dzida
Format: Article
Language:English
Subjects:
cardiovascular effects
glucose
sodium-glucose co-transporter 2 inhibitors
type 2 diabetes
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antihyperglycemic interventions have centered on increasing insulin availability, improving insulin sensitivity or restoring β-cell activity to normalize plasma glucose levels in patients with type 2 diabetes mellitus. An alternative strategy is to enhance urinary glucose excretion by targeting renal sodium-glucose co-transporters (SGLTs). Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce blood glucose by increasing urinary glucose excretion and present a valuable therapeutic option for the treatment of type 2 diabetes. Presently, clinically available SGLT2 inhibitors include canagliflozin, dapagliflozin and empagliflozin.
ISSN:2391-8306